<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000488'>Retinopathy</z:hpo> is the most common microvascular complication of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and is an important cause of <z:hpo ids='HP_0000618'>blindness</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical trials have demonstrated that tight metabolic control inhibits the progression of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Good blood pressure control has been shown to be protective in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and it may also reduce proliferative <z:hpo ids='HP_0000488'>retinopathy</z:hpo> in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>However, such control is often difficult to achieve in clinical practice, and may be associated with problems such as <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>New therapies are therefore needed to reduce the risk of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>There is growing evidence that the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) plays an important role in the pathogenesis of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, and this has led to interest in <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors as agents to prevent <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Several trials have suggested that <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> therapy can inhibit progression of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The Diabetic <z:hpo ids='HP_0000488'>Retinopathy</z:hpo> <z:chebi fb="0" ids="3347">Candesartan</z:chebi> Trials (DIRECT) Programme is currently investigating the effects of the <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker <z:chebi fb="0" ids="3347">candesartan</z:chebi> on the incidence of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and its progression in type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>It is hoped that the results from such large-scale clinical trials will provide more specific information about the medical treatment of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
</text></document>